India to Saudi Arabia: Ustekinumab Export Trade Route

The India to Saudi Arabia Ustekinumab corridor is one of India's established pharmaceutical export routes, with 10 shipments documented worth a combined $125.8K USD. The route is dominated by AMERICAN MIDDLE EASTERN MEDICAL SOLUTIONS PRIVATE, which alone accounts for roughly 46% of all export value, reflecting the consolidated nature of India's ustekinumab manufacturing sector.

Across 3 active suppliers, the average shipment value stands at $12.6K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Freight is split between sea (69%) and air (18%), suggesting a mix of scheduled bulk orders and time-sensitive consignments.

Shipment activity peaks during July–September, with an average transit time of 15 days port-to-port. The route has recorded an annual growth rate of 21.8%, placing it at rank #3 among India's top ustekinumab export destinations globally.

On the import side, key buyers of Indian ustekinumab in Saudi Arabia include TO THE ORDER OF, TO THE CONSIGNEE-, KING ABDUL AZIZ MEDICAL CITY. TO THE ORDER OF is the single largest importer with 7 shipments valued at $65.6K USD.

India's ustekinumab exports to Saudi Arabia are driven primarily by a handful of large-scale manufacturers. AMERICAN MIDDLE EASTERN MEDICAL SOLUTIONS PRIVATE with 7 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 3 active exporters signals a competitive but concentrated market — buyers in Saudi Arabia benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — AMERICAN MIDDLE EASTERN MEDICAL SOLUTIONS PRIVATE, ZYPHAR'S PHARMACEUTICS PRIVATE LIMITED, MODERN DRUG HOUSE — together account for 100% of total trade value on this route. The average shipment value of $12.6K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

Beyond the primary product category, shipments on this route include closely related formulations such as pharmaceutical harmless product vial ustekinumab solution for intravenous infusion brand :stelara 130mg/26ml and asper invoice no: zppl/xp/2425/143 date:20/06/2024 sr no. 1 ustekinumab solution for intravenous infusion 130mg/26ml, suggesting that buyers in Saudi Arabia tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, TO THE ORDER OF is the largest importer with 7 shipments worth $65.6K USD — representing 52% of all ustekinumab imports from India on this route.